ChromaDex (CDXC)
(Real Time Quote from BATS)
$3.67 USD
+0.12 (3.38%)
Updated Sep 19, 2024 09:56 AM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum C VGM
Price, Consensus and EPS Surprise
CDXC 3.67 +0.12(3.38%)
Will CDXC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CDXC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CDXC
Is Brainsway (BWAY) Stock Outpacing Its Medical Peers This Year?
ChromaDex (CDXC) Reports Break-Even Earnings for Q2
CDXC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates
ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
Other News for CDXC
ChromaDex expands pharmaceutical-grade Niagen IV, injection offerings
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen? IV and Injection Offerings to Additional Leading Wellness Clinics
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
ChromaDex to Participate in Renmark?s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+